Cardiff Oncology (CRDF) 8-K Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

AGENDA Q4 2023 Financial Results and ONSEMBLE Trial Data

risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber- attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

1. 2023 was a transformational year 2. New data release from 2nd line ONSEMBLE trial 3. Review of financial position AGENDA

August: mCRC September: beyond mCRC

FIRST LINE SECOND LINE

FIRST LINE SECOND LINE

FIRST LINE SECOND LINE

FIRST LINE SECOND LINE

EXISTING DATA NEW DATA FUTURE POTENTIAL FIRST LINE SECOND LINE

NEW DATA 28 DAY CYCLE ENROLLMENT CRITERIA PRIMARY ENDPOINT

NEW DATA Enrollment*

NEW DATA 1st LINE 2nd LINEBev exposed vs bev naïve patients

NEW DATA —

NEW DATA —

NEW DATA —

NEW DATA —

NEW DATA Best response of: PR SD PD

NEW DATA Best response of: PR SD PD

NEW DATA

HIF1aα α Tumor growth Hypoxia α

HIF1aαTumor growth Hypoxia α bevacizumab onvansertib α

FUTURE POTENTIAL EXISTING DATA NEW DATA FIRST LINE SECOND LINE

FUTURE POTENTIAL

FUTURE POTENTIAL Standard of Care

FUTURE POTENTIAL ENROLLMENT CRITERIA ENDPOINTS PFIZER IGNITE 28 DAY CYCLE

Appendix Additional ONSEMBLE data

NEW DATA Bev Naïve Bev Exposed B e v N a ïv e B e v E xp o se d

NEW DATA Best response of: PR SD PD

NEW DATA Control arm

NEW DATA Experimental arm

NEW DATA • • Experimental arm